Non-Invasive Monitoring of Brain Dopamine Levels ID: 2018-057

Revolutionizing the diagnosis and management of dopamine-dependent disorders through non-invasive blood biomarkers.

Technology Overview

This research project focuses on developing a groundbreaking method to monitor brain dopamine levels non-invasively by identifying and utilizing dopamine D2 receptors (D2Rs) expressed in leukocytes as biomarkers. Through correlating D2R expression in leukocytes with brain dopamine levels, using both animal models and human subjects, this approach seeks to offer a cost-effective, reliable alternative to current diagnostic methods for conditions such as Parkinson's Disease.

Key Advantages

• Non-invasive and patient-friendly compared to current diagnostic methods
• Cost-effective alternative to PET scans and other invasive procedures
• Potential for use in both clinical and home settings
• Enables real-time monitoring and management of dopamine-dependent disorders

Problems Addressed

• High cost and invasiveness of current diagnostic technologies for dopamine-related disorders
• Lack of accessible, real-time monitoring tools for patients with Parkinson's Disease and other dopamine-dependent conditions
• Difficulty in early diagnosis and continuous management of neurological disorders due to inadequate monitoring tools

Market Applications

• Diagnostic tools for Parkinson's Disease and other dopamine-dependent disorders
• Development of microfluidics devices for easy detection of D2Rs in blood samples
• Research tools in neurology and pharmacology for studying dopamine’s role in various conditions
• Home-based monitoring devices for patients requiring regular assessment of brain dopamine levels

Additional Information

Technology ID: 2018-057
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025